Why the study?
Does dexrazoxane prevent cardiotoxicity and tissue injuries in patients receiving anthracycline-based chemotherapy?
Does dexrazoxane prevent cardiotoxicity and tissue injuries in patients receiving anthracycline-based chemotherapy?
This review summarizes the historical, preclinical, and clinical background of dexrazoxane for preventing anthracycline-induced cardiotoxicity and extravasation injuries.
Answers are grounded in this paper and cite their sources.
Offers historical context for dexrazoxane; leaves open its current role pending updated randomized data.
For more than half a century, the different properties of dexrazoxane have captured the attention of scientists and clinicians. Presently, dexrazoxane is licensed in many parts of the world for two different indications: prevention of cardiotoxicity from anthracycline-based chemotherapy, and prevention of tissue injuries after extravasation of anthracyclines. This article reviews the historical, preclinical, and clinical background for the use of dexrazoxane for these indications.
No takes yet. Share an insight, caveat, or question.
Seppo W. Langer (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: